Published in Clin Chim Acta on July 05, 2011
Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther (2012) 1.01
Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren's Syndrome: Analysis of the Sjögren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken) (2016) 0.79
Coherent somatic mutation in autoimmune disease. PLoS One (2014) 0.78
A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand. Clin Rheumatol (2015) 0.76
Comparing Genomic Profiles of Women With and Without Fibromyalgia. Biol Res Nurs (2015) 0.76
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. Medicine (Baltimore) (2016) 0.75
Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology. Clin Rev Allergy Immunol (2017) 0.75
Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol (2005) 9.25
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Disruption of GW bodies impairs mammalian RNA interference. Nat Cell Biol (2005) 5.52
A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell (2002) 5.34
The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies. RNA (2003) 4.40
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation. J Cell Sci (2004) 3.31
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol (2012) 2.43
B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2009) 2.26
Utility of the Patient Health Questionnaire-9 to assess suicide risk in patients with systemic sclerosis. Arthritis Care Res (Hoboken) (2013) 2.14
Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol (2014) 1.99
Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum (2006) 1.99
Formation of GW bodies is a consequence of microRNA genesis. EMBO Rep (2006) 1.92
Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis (2009) 1.84
Small interfering RNA-mediated silencing induces target-dependent assembly of GW/P bodies. Mol Biol Cell (2007) 1.83
The C-terminal half of human Ago2 binds to multiple GW-rich regions of GW182 and requires GW182 to mediate silencing. RNA (2009) 1.69
The role of GW/P-bodies in RNA processing and silencing. J Cell Sci (2007) 1.63
High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J (2012) 1.62
Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum (2007) 1.61
Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev (2012) 1.60
Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum (2011) 1.55
Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing. J Cell Sci (2008) 1.53
Health services costs and their determinants in women with fibromyalgia. J Rheumatol (2004) 1.53
Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol (2005) 1.52
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther (2010) 1.50
Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther (2008) 1.47
Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) (2012) 1.41
Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther (2007) 1.40
Systemic sclerosis in Canada's North American Native population: assessment of clinical and serological manifestations. J Rheumatol (2013) 1.39
Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum (2008) 1.35
Autoimmune targeting of key components of RNA interference. Arthritis Res Ther (2006) 1.32
A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit (2004) 1.31
Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. J Mol Med (Berl) (2003) 1.25
Quality of life in systemic sclerosis: psychometric properties of the World Health Organization Disability Assessment Schedule II. Arthritis Rheum (2008) 1.23
Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer (2005) 1.21
Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. J Immunol Methods (2006) 1.20
Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev (2011) 1.19
The clinimetric properties of the World Health Organization Disability Assessment Schedule II in early inflammatory arthritis. Arthritis Rheum (2008) 1.18
Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum (2009) 1.18
Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci (2010) 1.17
The development of systemic sclerosis classification criteria. Clin Rheumatol (2007) 1.17
Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) (2010) 1.15
Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: internal consistency reliability, convergent validity and clinical correlates. Rheumatology (Oxford) (2010) 1.15
Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis Rheum (2007) 1.15
The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol (2012) 1.15
Primary ciliogenesis defects are associated with human astrocytoma/glioblastoma cells. BMC Cancer (2009) 1.13
Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. J Immunol Methods (2010) 1.13
Fragmentation of Golgi complex and Golgi autoantigens during apoptosis and necrosis. Arthritis Res (2002) 1.12
Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol (2013) 1.11
Office capillaroscopy in systemic sclerosis. Clin Rheumatol (2006) 1.11
A panel of monoclonal antibodies to cytoplasmic GW bodies and the mRNA binding protein GW182. Hybrid Hybridomics (2003) 1.09
Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum (2012) 1.09
Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther (2004) 1.08
Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol (2007) 1.08
Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol (2007) 1.07
Reliability and validity of the center for epidemiologic studies depression scale in patients with systemic sclerosis. Arthritis Rheum (2008) 1.07
Predictors of somatic symptoms in depressive disorder. Gen Hosp Psychiatry (2003) 1.06
Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin Immunol (2004) 1.06
Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun (2008) 1.06
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care Res (Hoboken) (2012) 1.06
GW bodies, microRNAs and the cell cycle. Cell Cycle (2006) 1.05
Autoantibodies in systemic sclerosis. Autoimmun Rev (2012) 1.05
The antinuclear antibody test: last or lasting gasp? Arthritis Rheum (2011) 1.05
The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther (2011) 1.04
Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthritis Rheum (2008) 1.03
Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda. Arthritis Care Res (Hoboken) (2010) 1.03
Cytoplasmic ribonucleoprotein (RNP) bodies and their relationship to GW/P bodies. Int J Biochem Cell Biol (2009) 1.03
Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int (2010) 1.03
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum (2009) 1.03
2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) (2015) 1.02
Unique and shared features of Golgi complex autoantigens. Autoimmun Rev (2005) 1.01
Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol (2009) 1.01
An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor. PLoS One (2013) 1.01
Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep (2012) 1.01